MedTrace Logo

Study of Radiolabeled Revumenib in Adults With Acute Leukemia

NCT05406817 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2025-01-10

No results posted yet for this study

Summary

This is an open-label study to evaluate the absorption, metabolism, and excretion (AME) of carbon-14 (\[14C\])-revumenib in participants with acute leukemia.

Conditions

Interventions

DRUG

Revumenib

Initial radiolabeled revumenib will be administered as an oral solution. Capsules will be administered thereafter.

Sponsors & Collaborators

Principal Investigators

  • Nicole McNeer, MD, PhD · Syndax Pharmaceuticals

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-05
Primary Completion
2024-11-18
Completion
2024-11-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05406817 on ClinicalTrials.gov